CBLL CERIBELL INC.

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time. 

Event: Bank of America Securities 2025 Health Care Conference

Date: Wednesday, May 14, 2025

Time: 10:55 a.m. PST / 1:55p.m. EST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at . 

About CeriBell, Inc.

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit or follow the company on .

Investor Contact

Brian Johnston or Laine Morgan

Gilmartin Group

Media Contact

Corrie Rose



EN
30/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERIBELL INC.

 PRESS RELEASE

Ceribell to Participate in the Bank of America Securities 2025 Health ...

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.  E...

 PRESS RELEASE

Ceribell Receives FedRAMP® High Authorization, Expanding Approval for ...

Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technolog...

 PRESS RELEASE

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025 SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested i...

 PRESS RELEASE

FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Makin...

FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older Powered by Clarity, the Ceribell System will enable rapid, bedside detection, diagnosis and treatment of non-convulsive seizures in children experiencing neurological emergencies SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurolog...

 PRESS RELEASE

Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results

Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 & Recent Highlights Reported total revenue of $18.5 million in the fourth quarter of 2024, a 41% increase compared to the same period in 2023Delivered total revenue of $65.4 m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch